Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCTR20200911003Phase 4Recruiting
Phase 4, single-arm trial of rivastigmine in Dementia, sponsored by Berlin Pharmaceutical. Primary endpoint: Incidence of skin sensitization. Started Sep 2020; status: recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on TCTR20200911003.